SCHEDULE 13G/A: Great Point Partners and Affiliates Maintain Significant Stake in Context Therapeutics Inc.

An amended Schedule 13G filing reveals that Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, collectively hold a 5.22% beneficial ownership in Context Therapeutics Inc.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Context Therapeutics Inc.
• The reporting persons collectively beneficially own 4,683,711 shares of Context Therapeutics Inc. Common Stock.
• This aggregate amount represents 5.22% of the outstanding Common Stock of Context Therapeutics Inc.
• The percentage is calculated based on 89,704,194 shares of common stock outstanding, as reported by Context Therapeutics Inc. in its Form 10-K filed on March 20, 2025.
• Great Point Partners, LLC serves as the investment manager for Biomedical Value Fund, L.P. (BVF) and Biomedical Offshore Value Fund, Ltd. (BOVF).
• BVF is the record holder of 3,044,412 shares, and BOVF is the record holder of 1,639,299 shares.
• Dr. Jeffrey R. Jay, as Senior Managing Member of Great Point, and Ms. Lillian Nordahl, as Managing Director of Great Point, have shared voting and investment power over these shares.
• The reporting persons disclaim beneficial ownership of the shares held by BVF and BOVF, except to the extent of their respective pecuniary interests.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Context Therapeutics Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

This filing reflects a routine disclosure of a significant institutional investment in a publicly traded biotechnology company. Such filings provide transparency into the ownership structure and the positions held by large investors, which is a common aspect of the financial markets, particularly in sectors like biotechnology where institutional capital plays a crucial role in funding research and development.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.

Key Dates

Keywords

Context Therapeutics Inc., CTXO, Great Point Partners, Jeffrey R. Jay, Lillian Nordahl, Schedule 13G, beneficial ownership, institutional investment, common stock, biotechnology, pharmaceutical